Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Net Cash Flow (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Net Cash Flow for 7 consecutive years, with $150.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 1143.52% to $150.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $139.3 million, a 325.3% increase, with the full-year FY2025 number at $139.3 million, up 325.3% from a year prior.
  • Net Cash Flow was $150.5 million for Q4 2025 at Fulcrum Therapeutics, up from $4.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $150.5 million in Q4 2025 to a low of -$55.8 million in Q4 2022.
  • A 5-year average of $7.0 million and a median of -$566000.0 in 2023 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 6189.58% in 2024; the steepest drop was 262.51% in 2024.
  • Fulcrum Therapeutics' Net Cash Flow stood at -$30.1 million in 2021, then crashed by 85.76% to -$55.8 million in 2022, then surged by 91.91% to -$4.5 million in 2023, then crashed by 219.19% to -$14.4 million in 2024, then skyrocketed by 1143.52% to $150.5 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Net Cash Flow are $150.5 million (Q4 2025), $4.5 million (Q3 2025), and $414000.0 (Q2 2025).